|
Getting your Trinity Audio player ready...
|
Catheter Precision Inc. (NYSE American: VTAK), an innovative U.S. medical device firm focused on electrophysiology products, announced on May 7, 2024, a purchase order from the University of California San Diego Health System (UCSD) for its revolutionary LockeT product. Physicians, purchasing departments, and hospital staff are currently evaluating the LockeT product, recognizing the potential advantages of incorporating it into the overall UCSD health system.
On May 6, 2024, the stock slightly declined but closed on normal volume, still positioned above its 10-, 20-, 50-, and 200-Day Moving Averages (DMA), suggesting it is in breakout territory. Presently, it is trading in the mid fifty-cent range, nearing its 52-week high of $1.33, which may be approached again soon, marking it as a stock to keep an eye on.
This purchase order follows another announcement on April 24 by Catheter Precision for the LockeT product, purchased by HCA Healthcare Inc. (NYSE: HCA). HCA Healthcare Inc. is one of the largest healthcare service providers in the United States, generating revenues of $64 billion in 2023.
HCA Healthcare Inc. is considered one of the more discerning organizations in the healthcare industry regarding product evaluations. Therefore, the approval of the LockeT product within HCA’s national healthcare system marked a significant milestone for Catheter Precision.
Related posts:
Stocks in the News: “Key Developments to Watch This Week: CLNV, INBS, VTAK, HALB, SNNC
“Market Movers: Top Stocks Making Headlines This Week” – KAVL, INBS, VTAK, CLNV
Medical Spotlight: Catheter Precision, Inc. (NYSE American: VTAK) Showcased in EP Lab Digest, Fuelling Positive Market Momentum”
Market Spotlight: Catheter Precision Inc (NYSE American: VTAK) Emerges as a Key Stock to Watch
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates ‘Buy’ for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN